Electra Therapeutics ^{Filed, US Offering, Nasdaq: ETRA}

We are a late clinical-stage biopharmaceutical company developing precision medicines for the treatment of immune-mediated diseases and cancer. Our approach targets signal regulatory proteins ("SIRP"), a family of cell surface receptors whose expression is restricted to specific immune cell populations, and increases upon activation to enable selective depletion of disease-driving cells while preserving normal immune function. Our lead product candidate is ipsoprubart, a pan-SIRP monoclonal antibody designed to selectively deplete pathological myeloid cells and T cells via binding to SIRPa/ß1/g, currently in a global registrational program for patients with secondary hemophagocytic lymphohistiocytosis ("sHLH"). In our Phase 1b trial, ipsoprubart was generally well tolerated and demonstrated a 100% 8-week overall survival rate and 100% overall response rate in 12 frontline patients with malignancy-associated HLH, the largest subset of sHLH and the population associated with the poorest outcomes. We are conducting SURPASS, our global Phase 2/3 registrational trial in newly diagnosed, treatment-naïve sHLH patients, as well as COMPASS, a natural history study designed to provide an external control comparator for SURPASS, and expect to complete enrollment in the second half of 2027. Ipsoprubart has received Breakthrough Therapy designation from the FDA and PRIority MEdicine designation from the EMA, each granted for the treatment of sHLH broadly. We are also conducting a Phase 1 trial evaluating ipsoprubart as a monotherapy in patients with relapsed/refractory T cell and natural killer cell malignancies, with initial data expected in the second half of 2027.